ASND vs JAZZ
Ascendis Pharma A/S and Jazz Pharmaceuticals plc, both Healthcare
Ascendis Pharma A/S is the larger company at $15B against $14B. Over the past year JAZZ returned +123% against +32% for ASND. Ryufin's sector-relative Smart Score puts ASND ahead, 8/10 against 6/10.
| Figure | ASND | JAZZ |
|---|---|---|
| Last close | $250 | $249 |
| Market cap | $15B | $14B |
| 1-year return | +32% | +123% |
| 5-year return | +108% | +46% |
| Ryufin Smart Scoresector-relative, 1–10 | 8/10 | 6/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Ascendis Pharma A/S
Revenue of $248M in Q4 2025, net income null.
Jazz Pharmaceuticals plc
Revenue of $1.1B in Q1 2026, net income $293M. Its largest reported line is Oncology, 31% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.